Clinical Trials Logo

Nephritis clinical trials

View clinical trials related to Nephritis.

Filter by:

NCT ID: NCT06445127 Recruiting - Lupus Nephritis Clinical Trials

Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)

Start date: May 7, 2024
Phase: N/A
Study type: Interventional

This study is being done to find out if a non-invasive Magnetic Resonance Imaging (MRI) examination of the kidneys may be helpful for diagnosing lupus nephritis in patients with systemic lupus erythematosus (SLE). Participation involves having a kidney MRI that will take between 30 to 60 minutes. Participants may have 1-4 kidney MRIs over a 6-month time period.

NCT ID: NCT06429800 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis

Start date: October 31, 2024
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety and preliminary efficacy of ATA3219 (following lymphodepletion) for treatment of participants with lupus nephritis (LN).

NCT ID: NCT06428539 Not yet recruiting - Lupus Nephritis Clinical Trials

T Regulatory Cells IN LUPUS NEPHRITIS

Start date: July 1, 2024
Phase:
Study type: Observational

- To study the role FoxP3-positive T regulatory cells in the pathogenesis of Lupus Nephritis, and determine the factors associated with levels of T regs . - To compare the functional capacity of T regs in LN and in normal individuals.

NCT ID: NCT06419205 Not yet recruiting - IgA Nephropathy Clinical Trials

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

Start date: June 2024
Phase: Phase 2
Study type: Interventional

A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 18 Years or Older With Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)

NCT ID: NCT06406205 Recruiting - Lupus Nephritis Clinical Trials

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

Start date: December 25, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy of QL1074 compared with placebo in achieving renal response after 52 weeks of therapy in subjects with Active Lupus Nephritis.

NCT ID: NCT06377228 Not yet recruiting - Clinical trials for Refractory Lupus Nephritis

A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN)

Start date: November 1, 2024
Phase: Phase 1
Study type: Interventional

The main aim of the study is to learn how well adults with refractory lupus nephritis (LN) tolerate TAK-007 and to check for side effects (adverse events). Other aims are to learn how effective treatment with TAK-007 is in adults with refractory LN, what effects TAK-007 has on the human body, and whether participants will produce antibodies against TAK-007.

NCT ID: NCT06375993 Not yet recruiting - Autoimmune Diseases Clinical Trials

A Phase 1 Study of ADI-001 in Lupus Nephritis

Start date: June 2024
Phase: Phase 1
Study type: Interventional

ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion safety/efficacy study in patients with lupus nephritis. The study will consist of different periods including screening, lymphodepletion, treatment, and follow-up

NCT ID: NCT06350110 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

BAH242
Start date: November 10, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002 injection (CD19-BCMA CAR-T cells) that patients suffering from resistant systemic lupus erythematosus can tolerate.

NCT ID: NCT06342960 Recruiting - Lupus Nephritis Clinical Trials

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis (KYSA-3)

Start date: December 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis

NCT ID: NCT06288308 Not yet recruiting - Lupus Nephritis Clinical Trials

Fibrinogen to Albumin Ratio (FAR) as a Predictive Biomarker for Lupus Nephritis (LN)

Start date: March 20, 2024
Phase:
Study type: Observational

Fibrinogen to Albumin ratio as a predictive biomarker for lupus nephritis (LN)